-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 27, Novartis announced the results for the first quarter of 2021.
Novartis' current business is divided into two main lines: innovative drugs and generic drugs.
From the perspective of specific products, the rheumatoid immune disease treatment drug Cosentyx (skucilumab) and the new heart failure drug Entresto (sacquatril valsartan) contributed a total of 1.
Zolgensma, a gene therapy for spinal muscular atrophy, has benefited from geographical penetration and is currently in an outbreak, with a double-digit growth rate of 88% reaching US$319 million.
In addition, Novartis mentioned in its financial report the PD-1 tislelizumab introduced from BeiGene on January 12.